Potent anti-leukemia activities of chimeric antigen receptor modified T (CAR-T) cell therapy in Chinese patients with relapsed/refractory hematological malignances
subjects with non-Hodgkin's Lymphoma (NHL) were treated by autologous CD19 murine CAR-T cells (NCT 02813837). Another two subjects with r/r B-ALL were treated by autologous ... CD19 humanized CAR-T cells. Methods: 41…

